A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer
This phase II trial studies how well cabozantinib-s-malate works in treating patients with
endometrial cancer that has come back (recurrent) or has spread to other places in the body
(metastatic). Cabozantinib-s-malate may stop the growth of tumour cells by blocking some of
the enzymes needed for cell growth and by blocking blood flow to the tumour.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society